%0 Journal Article
%T Use of Cox¡¯s Cure Model to Establish Clinical Determinants of Long-Term Disease-Free Survival in Neoadjuvant-Chemotherapy-Treated Breast Cancer Patients without Pathologic Complete Response
%A Junichi Asano
%A Akihiro Hirakawa
%A Chikuma Hamada
%A Kan Yonemori
%A Taizo Hirata
%A Chikako Shimizu
%A Kenji Tamura
%A Yasuhiro Fujiwara
%J International Journal of Breast Cancer
%D 2013
%I Hindawi Publishing Corporation
%R 10.1155/2013/354579
%X In prognostic studies for breast cancer patients treated with neoadjuvant chemotherapy (NAC), the ordinary Cox proportional-hazards (PH) model has been often used to identify prognostic factors for disease-free survival (DFS). This model assumes that all patients eventually experience relapse or death. However, a subset of NAC-treated breast cancer patients never experience these events during long-term follow-up (>10 years) and may be considered clinically ¡°cured.¡± Clinical factors associated with cure have not been studied adequately. Because the ordinary Cox PH model cannot be used to identify such clinical factors, we used the Cox PH cure model, a recently developed statistical method. This model includes both a logistic regression component for the cure rate and a Cox regression component for the hazard for uncured patients. The purpose of this study was to identify the clinical factors associated with cure and the variables associated with the time to recurrence or death in NAC-treated breast cancer patients without a pathologic complete response, by using the Cox PH cure model. We found that hormone receptor status, clinical response, human epidermal growth factor receptor 2 status, histological grade, and the number of lymph node metastases were associated with cure. 1. Introduction Neoadjuvant chemotherapy (NAC) was introduced first in the early 1980s to improve tumor operability in patients with locally advanced breast cancers [1]. Recently, NAC applications have been extended to already-operable cases [1]. According to a previous meta-analysis of 9 randomized trials, NACs and adjuvant chemotherapies were equally effective in terms of overall survival (OS) and disease-free survival [2]. Breast cancer relapses or metastases were reported in only 34% of the patients within 8 years of NAC treatment [3], whereas a subset of NAC-treated primary breast cancer patients were reported to achieve long-term disease-free survivals (DFS) [3]. Accordingly, these patients did not experience recurrences, metastases, or death during the long-term follow-up study (e.g., for over 10 years) and were clinically ¡°cured.¡± Although the prognostic factors for DFS have been established by several previous reports [4¨C9], clinical determinants of cure have not been studied adequately. In prognostic studies for breast cancer patients treated with NAC, the Cox proportional-hazards (PH) model has been often used to identify the prognostic factors for DFS. The ordinary Cox PH model assumes that all patients will eventually experience relapse or death. Therefore, the ordinary
%U http://www.hindawi.com/journals/ijbc/2013/354579/